摘要
Abstract
Objective:To evaluate the clinical efficacy and safety of vericiguat combined with eszopiclone in patients with heart failure complicated by insomnia.Methods:A total of 80 patients with heart failure and concomitant insomnia admitted to the Third Affiliated Hospital of Inner Mongolia Medical University from January 2023 to January 2025 were selected and randomly divided into a control group and an observation group(40 cases each)using the random number table method.All patients received stand-ard pharmacological therapy for heart failure.The control group was treated with oral eszopiclone for insomnia,while the observa-tion group received vericiguat in addition to eszopiclone.The Pittsburgh Sleep Quality Index(PSQI)was used to assess sleep qual-ity,the Insomnia Severity Index(ISI)to evaluate insomnia symptoms,and the Epworth Sleepiness Scale(ESS)to measure daytime sleepiness.Polysomnography(PSG)was performed to analyze sleep architecture,including the proportions of N1(light sleep stage 1),N2(light sleep stage 2),N3(deep sleep stage),and REM(rapid eye movement sleep).Cardiac function was assessed using left ventricular ejection fraction(LVEF),N-terminal pro-B-type natriuretic peptide(NT-proBNP),and the 6-minute walk test(6MWT).Adverse reactions such as dizziness/somnolence,hypotension,bradycardia,and nausea/vomiting were recorded.Results:After treatment,PSQI,ISI,and ESS scores decreased significantly in both groups,with lower scores in the ob-servation group than in the control group(P＜0.05).The proportion of N1 and REM sleep stages and the arousal index were sig-nificantly reduced,while N2 and N3 stage proportions increased,with greater improvement in the observation group(P＜0.05).LVEF and 6MWT results increased in both groups after treatment,with higher values in the observation group(P＜0.05).NT-proBNP levels decreased in both groups,and were significantly lower in the observation group(P＜0.05).The incidence of dizzi-ness/somnolence was significantly lower in the observation group compared with the control group(P＜0.05).Conclusion:The combination of vericiguat and eszopiclone in patients with heart failure complicated by insomnia can comprehensively improve sleep quality and cardiac function,while demonstrating higher safety and good clinical applicability.关键词
维立西呱/右佐匹克隆/心功能不全/失眠/安全性/睡眠质量/疗效Key words
Vericiguat/Eszopiclone/Heart failure/Insomnia/Safety/Sleep quality/Efficacy分类
医药卫生
